Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Aerpio Therapeutics
Age
18–70
Sex
ALL
Healthy volunteers
Accepted
You may be eligible if
Aged \> 18 years to 70 years inclusive in Cohort 1; aged ≥ 45 to 70 years inclusive in Cohorts 2-4, aged 18 to 80 years inclusive in Cohort 5.
For subjects in Cohort 1, IOP between 12 and 23 mm Hg (inclusive). For subjects in Cohorts 2-4, IOP between 16 and 23mm Hg (inclusive). For subjects in Cohort 5, IOP between 17 and 27 mm Hg (inclusive).
Central corneal thickness of 480 to 600 μm, inclusive
For subjects in Cohort 5, diagnosis of OAG or OHT
For subjects in Cohort 5, currently receiving prostaglandin therapy for IOP lowering
You may not be if
Diagnosis of any form of glaucoma in Cohorts 1-4
Clinically significant eye trauma within 6 months of screening
Any intraocular ophthalmic procedure within 6 months of screening
Any ocular inflammation within 90 days of screening or a history of recurrent uveitis in either eye
Subjects with any known chronic ocular disease (other than incipient cataract or refractive error)
Any condition preventing valid applanation tonometry measurement, e.g., clinically significant corneal disease, refractive surgery
Visual acuity (VA) worse than 20/30 in either eye, For Cohort 5 VA worse than 20/100 in either eye
Clareo Health | Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AKB-9778 Ophthalmic Solution
